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Tumor epithelial cells develop within a microenvironment consist-
ing of extracellular matrix, growth factors, and cytokines produced
by nonepithelial stromal cells. In response to paracrine signals from
tumor epithelia, stromal cells modify the microenvironment to pro-
mote tumor growth and metastasis. Here, we identify interleukin 33
(IL-33) as a regulator of tumor stromal cell activation and mediator of
intestinal polyposis. In human colorectal cancer, IL-33 expression was
induced in the tumor epithelium of adenomas and carcinomas, and
expression of the IL-33 receptor, IL1RL1 (also referred to as IL1-R4
or ST2), localized predominantly to the stroma of adenoma and
both the stroma and epithelium of carcinoma. Genetic and antibody
abrogation of responsiveness to IL-33 in the ApcMin/+mouse model of
intestinal tumorigenesis inhibited proliferation, induced apoptosis,
and suppressed angiogenesis in adenomatous polyps, which reduced
both tumor number and size. Similar to human adenomas, IL-33 ex-
pression localized to tumor epithelial cells and expression of IL1RL1
associated with two stromal cell types, subepithelial myofibroblasts
and mast cells, in ApcMin/+ polyps. In vitro, IL-33 stimulation of human
subepithelial myofibroblasts induced the expression of extracellular
matrix components and growth factors associated with intestinal
tumor progression. IL-33 deficiency reduced mast cell accumulation
in ApcMin/+ polyps and suppressed the expression of mast cell-derived
proteases and cytokines known to promote polyposis. Based on
these findings, we propose that IL-33 derived from the tumor epithe-
lium promotes polyposis through the coordinated activation of stro-
mal cells and the formation of a protumorigenic microenvironment.
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Colorectal cancer (CRC) is a leading cause of cancer-relateddeaths worldwide. The origins of hereditary colon cancer
(familial adenomatous polyposis) as well as sporadic CRC are
closely associated with mutations in the adenomatous polyposis coli
(APC) tumor suppressor gene (1, 2). Subsequent loss of hetero-
zygosity for APC in intestinal epithelial cells (IECs) activates Wnt
signaling through stabilization of β-catenin, which is sufficient to
initiate polyp formation (3). Although genetic alterations in IECs
are a driving force of dysplasia, intestinal tumors are rarely, if ever,
entirely composed of a genetically altered epithelium. Rather, a
host of ancillary cells including gut mesenchymal cells [e.g.,
smooth muscle cells, endothelial cells, and subepithelial myofi-
broblasts (SEMFs)] as well as mucosal immune cells are inter-
mingled with the tumor epithelial cells. Importantly, these stromal
cells regulate the tumor microenvironment to influence CRC ini-
tiation and progression (4, 5).
Stromal cells of the normal intestinal mucosa have an inherent
ability to rapidly react to changes in epithelial cell homeostasis.
In response to tissue damage such as infection, the stromal com-
partment produces cytokines and chemokines, extracellular matrix
(ECM) proteins, ECM remodeling molecules, and growth factors
to coordinate immune responses and mediate tissue repair through
epithelial restitution and proliferation (6, 7). The CRC stroma
acquires a similar activated phenotype and produces the same
soluble factors and ECM components associated with inflammation
and wound healing to promote proliferation and survival of trans-
formed epithelia, tumor immune evasion, angiogenesis, and tissue
invasion and metastasis (5, 8, 9). Importantly, the tumor epithelium
directly activates stromal cells through the release of paracrine
factors and cytokines, such as transforming growth factor-β (TGFβ),
to establish a microenvironment favorable to tumor growth and
metastasis (4, 9–11). Thus, tumor epithelial cell-derived paracrine
factors that modulate stromal cell function are potential biomarkers
of disease prognosis as well as targets for anticancer therapy (9, 12).
Interleukin 33 (IL-33) is a member of the IL-1 family of cy-
tokines and is expressed in several organ systems including the
gastrointestinal tract (13). Nonhematopoietic cells, including epi-
thelial cells, myofibroblasts, fibroblasts, adipocytes, smooth muscle
cells, and endothelial cells, are the primary sources of IL-33 pro-
duction (14–16), but professional antigen-presenting cells such as
macrophages also express IL-33 (16). Similar to IL-1α, IL-33 is a
dual-function protein with roles as a nuclear factor and a classical
cytokine (17). IL-33 functions as a prototypic “alarmin,” passively
released by stressed, damaged, or necrotic cells to alert the immune
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system of a local threat such as trauma or infection (18, 19). As a
cytokine, IL-33 activates a heterodimeric receptor complex com-
prised of IL-1 receptor-like 1 (IL1RL1; also referred to as IL1-R4
or ST2L) and its coreceptor, IL-1 receptor accessory protein (IL-
1RAcp), which regulates inflammatory gene expression through
MAPK and NF-κB signaling cascades (16, 20). A splice variant of
IL1RL1 exists as a soluble isoform (commonly referred to as sST2)
and is proposed to act as an antagonistic decoy receptor for IL-33
(21). Several immune cells, including mast cells and T helper (Th) 2
lymphocytes, as well as nonhematopoietic cells, including epithelial
cells, myofibroblasts, and endothelial cells, express IL1RL1 (22).
IL-33 is an important mediator of inflammation and wound-
healing responses in several tissues. In the gastrointestinal tract,
IEC-derived IL-33 enhances mucosal barrier defense against
helminth parasites by augmenting type 2 immune responses and
Th2-associated interleukin production (e.g., IL-4 and IL-13), which
mediate parasite expulsion, activate wound-healing responses in
SEMFs, and promote IEC proliferation and mucus production for
epithelial restitution and repair (6, 16, 23). In inflammatory bowel
disease (IBD), in particular active ulcerative colitis, IL-33 expres-
sion is induced in IECs and infiltrating lamina propria mono-
nuclear cells of ulcerative lesions and SEMFs beneath active
lesions (24–28). Importantly, two recent studies have established a
positive correlation between IL-33/IL1RL1 expression levels and
human CRC progression and metastasis (29, 30). However, the
contribution of IL-33 to overall tumor risk remains to be directly
assessed, and the mechanisms by which IL-33 contributes to tumor
initiation and progression remain unexplored.
In the present study, we demonstrate that IL-33 is an impor-
tant cytokine mediator of intestinal tumorigenesis. In human and
mouse adenomas, IL-33 and IL1RL1 expression are shown
to localize primarily to the tumor epithelium and stroma, re-
spectively. Using both genetic and antibody suppression of IL-33
signaling in ApcMin/+ mice, cytokine IL-33 is shown to promote
polyposis and influence adenomatous cell (tumor epithelial cell)
proliferation and apoptosis and tumor-associated angiogenesis.
We demonstrate that IL-33 expression is induced in adenoma-
tous cells of ApcMin/+ polyps and that two stromal cell types
previously associated with intestinal tumorigenesis, SEMFs and
mast cells, express IL1RL1. In response to IL-33, SEMFs and
mast cells express ECM components and remodeling proteins,
growth factors, and angiogenesis regulators, and cytokines char-
acteristic of activated stroma and involved in tumorigenesis. Taken
together, our observations suggest that tumor epithelial cells coopt
IL-33–induced tissue repair responses to form a tumor microen-
vironment favorable to polyposis.
Results
IL-33 Expression Is Induced in Human CRC. We initially tested
whether IL-33 signaling is associated with CRC in humans. Using
quantitative PCR (qPCR), IL33 expression was found to be sig-
nificantly increased in adenocarcinomas and patient-derived CRC
cell lines compared with expression in adjacent normal tissues
(Fig. 1A). IL33 expression in cell lines was significantly higher than
that in both normal intestinal tissues and tumors, suggesting that
IL33 is enriched in the tumor epithelium. Reanalysis of IL33 ex-
pression in the CRC Affymetrix datasets published by Skrzypczak
et al. (31) produced similar results, with IL33 expression signifi-
cantly increased in CRC whole tissue biopsies and in laser-micro-
dissected CRC mucosa and crypt epithelium (Fig. 1B). Reanalysis
of IL-33 expression in the CRC Affymetrix datasets published by
Sabates-Bellver et al. (32) produced similar results (Fig. S1A). Im-
portantly, circulating levels of IL-33 were significantly increased in
CRC patients compared with healthy individuals (Fig. S1B).
Next, we used immunohistochemistry to examine the distri-
bution of IL-33 and IL1RL1 in CRC and adjacent normal tissue.
In normal tissue, IL-33 immunolabeling was observed in stromal
cells within the lamina propria but rarely in the epithelium (Fig.
1C). In adenoma and carcinoma, the tumor epithelium repre-
sented the major source of IL-33 expression (Fig. 1 D and E).
Tumor stromal cells, including endothelial cells, positive for IL-33
were rare. IL1RL1 expression in normal tissue was observed in
Fig. 1. IL-33 and IL1RL1 expression in human CRC. (A) qPCR analysis of IL33 expression in adjacent normal mucosa (Norm), adenocarcinoma (Ad), and cell lines
derived from adenocarcinomas (Cell line). Data plotted relative to norm ± SEM (n = 20–25). (B) IL33 expression in human whole mucosa or tumor tissue
biopsies and laser-microdissected mucosa and crypt epithelium. Ad, colon adenoma or adenocarcinoma; Car, colon carcinoma; Norm, adjacent normal tissue.
Data obtained from the Skrzypczak and Skrzypczak 2 colorectal oncomine datasets. Bars indicate the mean. †P ≤ 0.01; ‡P ≤ 0.001; #P ≤ 0.0001. (C–E) Im-
munohistochemistry for IL-33 in normal adjacent mucosa, adenoma, and carcinoma. Insets show endothelial cells associated with vessels. Arrows indicate
IL-33–positive epithelium; arrowheads indicate IL-33–positive endothelial cells. (F–H) Immunohistochemistry for IL1RL1 in normal adjacent mucosa (Normal),
adenoma, and carcinoma. Insets show endothelial cells associated with vessels. Arrows indicate IL1RL1-positive epithelium; dashed arrows indicate stromal
cells. (Scale bars, 50 μm.)
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some stromal cells of the lamina propria and rarely within the
epithelium (Fig. 1F). In adenomas, IL1RL1 expression localized
predominately to stromal cells. Endothelial cell and adenoma-
tous cell immunostaining was rarely observed (Fig. 1G). In car-
cinoma, IL1RL1 immunolabeling of both carcinoma cells and
stromal cells was observed, and endothelial cell staining was in-
frequent (Fig. 1H). In summary, our analysis of IL-33 and IL1RL1
expression in CRC suggests that the epithelium is a major source
of IL-33 expression and that tumor-associated stromal cells pre-
dominately express IL1RL1. Thus, IL-33 appears to be an epi-
thelial cell-derived signal that modulates stromal cell function.
However, IL1RL1 expression in carcinoma cells suggests that as
CRC progresses the transformed epithelium also acquires the
capacity to respond to IL-33 autocrine/paracrine signals.
IL-33 Signaling Deficiency Reduces Polyp Burden in ApcMin/+ Mice. To
confirm our findings that IL-33 and IL1RL1 are expressed dur-
ing intestinal tumorigenesis, we next tested whether Il33 and
Il1rl1 are induced in adenomatous polyps of C57BL/6J (B6) mice
heterozygous for the ApcMinmutation. These mice (ApcMin/+) form
multiple intestinal adenomas following loss of heterozygosity for
Apc, similar to the initiation of most sporadic human CRC and
familial adenomatous polyposis (33). Il33 expression increased
twofold in the polyps of ApcMin/+ mice compared with normal
intestinal mucosa of wild-type (WT) littermates (Fig. 2A). In
addition, we measured expression of Ilrl1 in ApcMin/+ polyps.
Expression of membrane-associated and -soluble Il1rl1 isoforms
were increased 10- and 17-fold, respectively, in ApcMin/+ polyps
compared with normal intestinal mucosa (Fig. 2 B and C).
Thus, Il33 and Il1rl1 expression are also induced during polyposis
in mice.
Given the increased expression of Il33 and Il1rl1 in polyps of
ApcMin/+ mice, we next tested whether IL-33 signaling deficiency
blocks polyposis. B6 mice heterozygous for a null allele of Il33
(Il33+/−) (Fig. S2 A–C) were first crossed with B6-ApcMin/+ mice
to produce B6-ApcMin/+,Il33+/− offspring. B6-ApcMin/+,Il33+/−mice
were then crossed to B6-Il33+/− mice to produce experimental
ApcMin/+ mice deficient for Il33 (ApcMin/+,Il33−/−) and littermate
controls (ApcMin/+,Il33+/+ and ApcMin/+,Il33+/−). Il33 transcripts
were not detected in Il33−/− mice, verifying that the engineered
mutation is a null allele (Fig. 2A).
First we tested whether heterozygosity for the Il33 deletion
significantly affects polyposis. At 90 d of age, polyp initiation
(number) and progression (size) were indistinguishable between
control ApcMin/+,Il33+/+ and ApcMin/+,Il33+/− siblings (Fig. S3 A
and B). Thus, ApcMin/+,Il33+/+ and ApcMin/+,Il33+/− data were
pooled in further analyses. Next, we investigated whether Il33
deficiency inhibited polyposis. At 90 d of age, a 33% and 11%
reduction in polyp number and size, respectively, was observed in
experimental ApcMin/+,Il33−/− mice compared with ApcMin/+,Il33+/+
and ApcMin/+,Il33+/− control siblings (Fig. 2 D and E and Fig. S3C).
Because IL-33 is proposed to have dual roles as a chromatin-
associated nuclear factor and a cytokine (17), we used an IL1RL1
antagonist antibody (34) to test whether the cytokine function of
IL-33 promotes polyposis. B6-ApcMin/+ mice were treated with
150 μg of an anti-IL1RL1 antibody or IgG control twice a week
from 21 to 90 d of age. At this time point, anti-IL1RL1 treatment
significantly reduced polyp number by 55% and polyp size by 8%
(Fig. 2 D and E and Fig. S3C). Thus, based on the results of two
independent strategies for blocking IL-33 signaling, we find that the
cytokine function of IL-33 is an important mediator of intestinal
polyposis.
Various cytokines associated with polyposis stimulate IEC
proliferation and survival (4, 35). Therefore, we used BrdU in-
corporation and TUNEL assays to compare cell proliferation
and apoptosis, respectively, in ApcMin/+,Il33+/+ control and
ApcMin/+,Il33−/− test polyps. Il33 deficiency caused a 56% re-
duction in the number of mitotic cells (Fig. 2F and Fig. S4A) and
a 46% increase in apoptotic cell number in polyps (Fig. 2G and
Fig. S4B). Previous studies have suggested that IL-33 signaling
induces angiogenesis (36), which facilitates tumor growth and
metastasis. Thus, the surface area of von Willebrand Factor (vWF)
immunostained blood vessels in polyp sections was calculated for
ApcMin/+,Il33+/+ control and ApcMin/+,Il33−/− test mice. Impor-
tantly, IL-33 deficiency significantly reduced mean vessel surface
area by 42% in polyps (Fig. 2H and Fig. S4C). Together these
results suggest that IL-33 signaling promotes tumor growth and
associated angiogenesis.
Adenomatous Cells Express IL-33 in ApcMin/+ Polyps. Expression of
IL-33 in the gut mucosa has been localized to IECs, endothelial
cells, SEMFs, and lamina propria mononuclear cells (25, 26). In
IBD, in particular ulcerative colitis lesions, previous studies
revealed that IECs and SEMFs express IL-33 (25, 26, 28).
Therefore, we investigated whether IL-33 expression is also in-
duced in IECs and SEMFs during polyposis. In the normal small
intestine mucosa of WT mice, IL-33 expression localized to
stromal cells (mononuclear immune cells and fibroblast-like
cells) of the lamina propria but was minimally detectable in
IECs, which were identified by membranous-associated β-catenin
Fig. 2. IL-33 signaling deficiency attenuates polyp growth, induces apo-
ptosis, and suppresses angiogenesis. (A–C) qPCR analysis of Il33, membrane-
bound Il1rl1, and soluble Il1rl1 expression in normal mucosa of WT mice and
in adenomas of ApcMin/+ mice WT (+/+) or deficient (−/−) for Il33, or treated
with an IgG control (Cnt) or Il1rl1 antagonist (Ant) antibody. Expression is
plotted relative to WT ± SEM (n = 5–10). Average polyp number (D) and size
(E) in the small intestines and colons of ApcMin/+ mice WT and heterozygous
for the Il33 deletion (+/+ and +/−), homozygous for the Il33 deletion (−/−),
treated with a control (Cnt) antibody, or treated with the Il1rl1 antagonist
antibody (Ant). Bars indicate the mean in panel A. (F) Proliferative indices
(BrdU incorporation), (G) apoptotic (TUNEL labeling) indices, and (H) an-
giogenesis assessment (size vWF-positive area/size of tumor area) in polyps
from ApcMin/+ mice WT or deficient for Il33. For panels F–H, data are plotted
as the percentage of positive cells or total vessel area per section ± SEM
(n =16). *P ≤ 0.05; †P ≤ 0.01; ‡P ≤ 0.001; #P ≤ 0.0001.



























(CTNNB1) (Fig. 3A). Similarly, normal epithelial cells in tissues
surrounding polyps and in deep crypts under polyp lesions
remained IL-33–negative (Fig. 3A). In contrast, adenomatous
cells, which were identified by cytoplasmic and nuclear accu-
mulation of β-catenin, showed robust nuclear and cytoplasmic
expression of IL-33 (Fig. 3A).
Next we tested whether polyp-associated SEMFs are a source
of IL-33 expression. SEMFs exhibit features of both fibroblasts
and smooth muscle cells and are characterized by immunoreac-
tivity for smooth muscle actin (ACTA2) and vimentin (VIM)
but not desmin (DES) (37). Together these markers distin-
guish SEMFs from smooth muscle cells (ACTA2-positive, VIM-
negative, and DES-positive) and fibroblasts (ACTA2-negative,
VIM-positive, and DES-negative). In sections of normal gut
mucosa, IL-33 immunolabeling predominately localized to the
nuclei of pericryptal ACTA2- and VIM-positive SEMFs (Fig. 3B
and Fig. S5 A and B). Similarly, SEMFs surrounding deep crypts
under polyp lesions were positive for nuclear IL-33 (Fig. 3B and
Fig. S5 A and B). In contrast, SEMFs within polyps and sur-
rounding IL-33–expressing adenomatous cells did not express
detectable levels of IL-33 (Fig. 3B and Fig. S5B). We also
assessed the expression of IL-33 in smooth muscle and endo-
thelial cells in normal intestinal mucosa and polyps to exclude
these cell types as major contributors of IL-33 signaling. Im-
portantly, IL-33 staining was notably absent in all but a few DES-
positive smooth muscle cells or platelet/endothelial cell adhesion
(CD31)-positive endothelial cells in either tissue (Fig. S6 A and B).
To test whether tumor-associated stromal cells expressed IL-33 but
were negative for IL-33 immunolabeling due to constitutive cyto-
kine release, we used the beta-galactosidase (LacZ) reporter in the
IL-33 knockout allele (Fig. S2) to identify cells within polyps
transcriptionally active for IL-33. Immunolabeling for LacZ in
ApcMin/+ mice heterozygous for the IL-33 knockout allele con-
firmed that CTNNB1-positive adenomatous cells express LacZ
(Fig. S5 C and D). Few if any stromal cells, including ACTA2-
positve SEMFs, expressed LacZ (Fig. S5 C and E). In summary,
these results demonstrate that adenomatous cells represent the
vast majority of cells expressing IL-33 in ApcMin/+polyps.
SEMFs Express IL1RL1 in ApcMin/+ Polyps. Previous studies have
established that myofibroblasts in chronic pancreatitis tissues
express either IL-33 or IL1RL1 in response to different combi-
nations of cytokines (38). Based on evidence that myofibroblasts
have the capacity to express IL-33 or IL1RL1, we tested whether
polyposis in ApcMin/+ mice causes SEMFs to shift from an IL-33–
to an IL1RL1-positive cell population. In sections of normal
mucosa, IL1RL1 immunolabeling was weak to undetectable in
all cell types (Fig. 4 A and B). In contrast immunolabeling of
ApcMin/+ polyp sections revealed strong IL1RL1 localization to
stromal cells, with the highest levels of immunostaining localizing
to cells just beneath the surface epithelia (Fig. S7A). Coimmu-
nolabeling for IL1RL1 and SEMF markers ACTA2 and VIM
showed that IL1RL1-positive, periluminal stromal cells are
SEMFs (Fig. 4 A and B and Fig. S8). DES-positive smooth
muscle cells and CD31-positive endothelial cells were rarely
positive for IL1RL1 immunolabeling (Fig. S6 C and D). Impor-
tantly, Il33 deficiency reduced, but did not suppress, SEMF
immunolabeling for IL1RL1 in polyps, suggesting that IL-33 di-
rectly or indirectly regulates the expression of its own receptor in
SEMFs (Fig. S7 A and B). Together these results demonstrate that
SEMFs, in particular those in periluminal regions, are the primary
nonhematopoietic cell type expressing IL1RL1 in polyps.
SEMFs Express Genes Associated with Activated Stroma in Response
to IL-33. In the normal intestinal mucosa, SEMFs are positioned
subadjacent to the basement membrane and have a profound
influence on stem cell maintenance and IEC homeostasis (39).
During infection, trauma, and neoplasia, SEMFs are induced to
proliferate and release cytokines, growth factors, ECM compo-
nents, and angiogenesis factors that mediate IEC proliferation,
survival, differentiation, and repair (5, 39–41). Therefore, to test
whether IL-33 can also induce a gene expression profile indicative
of activated SEMFs, the human SEMF cell line (CCD-18Co) (42)
was cultured with recombinant human IL-33 or vehicle control and
then subjected to whole transcriptome sequencing (RNA-Seq).
Comparison of mRNA expression between IL-33– and control-
treated cells identified 1,357 transcripts that were differentially
expressed more than 1.5-fold (P < 0.05) (Dataset S1). Gene On-
tology (GO) Biological Processes and Kyoto Encyclopedia of
Genes and Genomes (KEGG) Pathway Analysis of the 699
transcripts up-regulated by IL-33 enriched for several annotations
associated with activation of stromal fibroblasts during tissue
repair and tumorigenesis, including ECM processing and re-
modeling, collagen metabolism, angiogenesis, and growth fac-
tor signaling (Table 1 and Dataset S2) (9, 10, 43). Curiously, the
658 transcripts down-regulated by IL-33 annotated into several
pathways associated with DNA repair (Table 1 and Dataset S3).
Interestingly, IL-33 treatment also induced SEMF expression
of transforming growth factor, beta 1 (TGFB1) (Dataset S1) and
the expression of several genes that annotated for TGFβ signal-
ing (Datasets S1 and S2). Several cell types in CRC, including IECs
and SEMFs, express TGFβ (9). TGFβ release into the tumor
microenvironment induces SEMF differentiation, migration, and
expression of genes (e.g., ANGPTL4, PTHLH, HBEGF, CTGF,
IL11, and TNC) known to promote metastasis of the tumor
epithelium (5, 11). Curiously, treatment of SEMFs with IL-33
increased the expression of these same TGFβ-regulated genes by
2–15-fold (P < 0.05). Importantly, IL-33 signaling also associated
with TGFβ-induced gene expression in vivo. Immunolabeling
ApcMin/+ polyp sections for tenacin-C (TNC), a downstream
target of TGFβ in intestinal SEMFs (44), revealed robust
localization of TNC to ACTA2-positive, periluminal SEMFs
(Fig. 4C). Serial sections demonstrated that the TNC-positive
SEMFs also express IL1RL1 and are adjacent to IL-33–posi-
tive tumor epithelia (Fig. 4C).
Fig. 3. IL-33 localizes to transformed epithelial cells in polyps and SEMFs in
normal mucosa. (A) Immunofluorescence for IL-33 (green) and CTNNB1 (red)
in WT (Normal) mucosa and an ApcMin/+ polyp. Adenomatous cells (nuclear
and cytoplasmic CTNNB1-positive) colabel for IL-33 (above the dashed line).
Normal IECs (membranous CTNNB1-positive) in deep crypts beneath a polyp
lesion are IL-33–negative (below the dashed line). (B) IL-33 (green) colo-
calized with the SEMF marker ACTA2 (red) in WT mucosa and normal mu-
cosa underlying ApcMin/+ polyp lesion (below the dashed line). SEMFs within
the lesion (above the dashed line) are IL-33–negative. For A and B, nuclei are
counterstained with DAPI and images are oriented with the intestinal lumen
at the top. (Scale bars, 50 μm.)
E2490 | www.pnas.org/cgi/doi/10.1073/pnas.1422445112 Maywald et al.
IL-33 Signaling Modulates Cytokine Expression in ApcMin/+ Polyps.
Because IL-33 is an important mediator of intestinal immunity
and IBD-associated inflammation (22), we next tested whether
tumor-elicited cytokine production is altered in the polyps of
Il33-deficient ApcMin/+ mice. IL-33 deficiency did not alter the
expression of the innate immune response cytokines tumor
necrosis factor (Tnf) and interleukin 1 beta (Il1b), Th1 immune
response cytokine interferon gamma (Ifng), or Th17 immune
response interleukins (Il17a, Il17f, Il22, and Il23) (Fig. S9 A–G).
However, expression of interleukins associated with Th2 immune
responses (Il4 and Il13) and chronic and tumor-elicited intestinal
inflammation (Il6) was significantly reduced in IL-33–deficient
polyps (Fig. 5 A–C). Interestingly, IL-33 signaling deficiency
also reduced expression of membrane-bound, but not -soluble,
Il1rl1 (Fig. 1D and E), suggesting that IL-33 regulates the isoform-
specific expression of its own receptor in target cells or that IL-33
influences the recruitment or proliferation of cells that express the
membrane-associated isoform. Similar changes in cytokine gene
expression were observed in IL1RL1 antagonist antibody-treated
ApcMin/+ polyps (Fig. 5 A–C and Fig. S9 A–G). Thus, abrogation of
responsiveness to IL-33 appears to primarily influence Th2-asso-
ciated cytokine production during polyposis.
IL-33 Signaling Contributes to Polyp-Associated Mastocytosis. Be-
cause IL-33 signaling deficiency suppressed Th2-associated cyto-
kine expression during polyposis, we sought to identify a cell type
associated with Th2 immune responses through which IL-33 sig-
naling may promote polyposis. IL1RL1 is expressed in the mast
cell lineage starting in committed progenitor cells and pro-
motes mast cell maturation, survival, granule accumulation,
tryptase production, and expression of Th2-associated cytokines
(45, 46). Previous studies showed that mast cells accumulate in
human and mouse intestinal adenomas and promote polyposis in
Apc mutant mouse models by regulating IEC homeostasis, stim-
ulating angiogenesis, and modulating immune responses within
the tumor microenvironment (47–49). Thus, we investigated the
effect of IL-33 signaling deficiency on mast cell activation and
recruitment in ApcMin/+ polyps.
In mice, mast cells are historically divided into two pop-
ulations, connective tissue mast cells and mucosal mast cells,
which are distinguished by the differential expression of several
chymases, tryptases, and proteases (50). Both cell types are
found within intestinal mucosa (47). To test whether IL-33 sig-
naling influences tumor-associated mast cell gene expression, we
measured the expression of connective tissue mast cell-associ-
ated chymase and tryptase (Cma1 and Tpsb2) and mucosal mast
cell-associated proteases (Mcpt4 and Mcpt2) in the polyps of
Il33-deficient, IL1RL1 antibody-treated, and control ApcMin/+
mice (Fig. 6 A and B and Fig. S9 H and I). In the polyps of
ApcMin/+,Il33+/+ and control antibody-treated ApcMin/+ mice,
expression of connective tissue and mucosal mast cell-related
genes was substantially increased 50–800-fold compared with
Fig. 4. Activated periluminal SEMFs in polyps express IL1RL1. Immunofluorescence for IL1RL1 (green) and the SEMF marker (A) ACTA2 or (B) VIM (red) in WT
(Normal) mucosa and an ApcMin/+ polyp. Polyp images on the Right are higher magnification images of theMiddle panels. SEMFs within the polyps are IL1RL1-
positive. (C) Immunofluorescence of polyp serial sections for the activated stroma marker TNC (green) and ACTA2, IL1RL1, or IL-33 (red). Periluminal SEMFs
adjacent to IL-33–positive epithelium coexpress TNC and IL1RL1. In all images nuclei are counterstained with DAPI, and arrowheads indicate regions of
colabeling. All images are oriented with the intestinal lumen at the top. (Scale bars, 50 μm).



























normal, WT mucosa. Importantly, both genetic and antibody
abrogation of responsiveness to IL-33 signaling caused a 10–70-
fold reduction in mast cell-associated gene expression in polyps.
To test whether IL-33 signaling directly induces mast cell gene
expression, we coimmunolabeled polyp sections for IL1RL1
and either tryptase, a connective tissue mast cell marker, or
mast cell protease 1 (MCPT1), a mucosal mast cell marker.
Both tumor-associated tryptase-positive and MCPT1-positive
mast cells expressed IL1RL1 (Fig. 6 C and D). Curiously,
however, mast cells within normal intestinal mucosa and polyps
of Il33-deficient ApcMin/+ mice did not express detectable levels of
IL1RL1 (Fig. S10), suggesting that IL-33 induces the expression of
its own receptor in mast cells during polyposis.
The significant reduction of mast cell gene expression in Il33-
deficient and antibody-treated polyps suggests that IL-33 in-
fluences mast cell activation, infiltration/expansion, or both.
Therefore, we used chloroacetate esterase (CAE) staining (51)
to identify and enumerate mast cells in polyps of Il33-deficient
and control ApcMin/+ mice (Fig. 6E). Importantly, polyps from
ApcMin/+,Il33−/− mice had fewer mast cells (fourfold reduction)
compared with ApcMin/+,Il33+/+ controls (Fig. 6F). Curiously, the
fourfold decrease in mast cell numbers resulting from IL-33
deficiency is substantially less than the 10–70-fold decrease in
mast cell gene expression observed in the same polyps (Fig. 6 A
and B and Fig. S9 H and I). IL-33 signaling, therefore, appears to
influence both mast cell accumulation and activation during
intestinal polyposis.
Discussion
Carcinogenesis commonly associates with suppression of cell-
mediated cytotoxic (Th1) immunity and enhanced humoral (Th2)
immunity (52). Deviation toward Th1 immunity promotes tumor
rejection by targeting and eliminating neoplastic cells (53). Con-
versely, deviation toward Th2 immunity suppresses antitumor im-
munity and promotes wound-healing responses that enhance
tumorigenesis (54–56). In patients with CRC, total numbers of
Th1 lymphocytes are decreased, Th1-associated cytokine pro-
duction is reduced, and Th2-associated cytokine production is
elevated (57–59). As CRC progresses, skewing toward Th2 im-
munity becomes more significant with Th2 cytokine levels, pre-
dictive of tumor reoccurrence and decreased disease-free survival
(59, 60). A similar imbalance between Th1- and Th2-mediated
immunity has been observed in the polyps of ApcMin/+ mice (61).
Compared with normal mucosa, Th1 cytokine expression is lower
or unchanged and Th2 cytokine expression is increased in polyps.
The mechanisms by which Th2 immunity is preferentially activated
during intestinal tumorigenesis are not well defined. However,
induction of prostaglandin-endoperoxide synthase 2 (COX-2) ex-
pression appears to play a role. COX-2–mediated production of
prostaglandin E2 (PGE2) suppresses Th1 responses and promotes
Th2 immunity in both human CRC and ApcMin/+ polyps (61–63).
However, the mechanisms through which PGE2 enhances Th2
immunity remain unresolved. Curiously, PGE2 has been shown to
induce IL-33 expression in dendritic cells (64). Thus, enhancement
of IL-33 expression within the tumor microenvironment may be
one mechanism through which PGE2 induces Th2-immune and
wound-repair responses that promote intestinal tumorigenesis.
A small but expanding body of evidence connects IL-33 sig-
naling and its enhancement of Th2 immunity and wound-healing
responses to tumorigenesis in several tissues (29, 30, 65–69). In the
present study, we demonstrate for the first time, to our knowledge,
that the IL-33 signaling axis is also an important modulator of
tumor initiation and progression in the intestine. In human and
ApcMin/+ adenomas, adenomatous cells were the primary source of
IL-33 expression, and stromal cells expressed IL1RL1. This cell
type distribution of IL-33 and its receptor mirrors the distribution
observed during mucosal type 2 immune and wound-healing re-
sponses to parasite infection (6) and fits a model in which tumor
Table 1. Pathway enrichment analysis of genes differentially
expressed by SEMFs in response to IL-33
Representative pathways enriched by
up- or down-regulated genes* P score
Up-regulated
Angiogenesis (BP) 9.68E-07
ECM–receptor interaction (Kegg) 7.60E-06
TGF-beta signaling pathway (Kegg) 3.33E-05
MAPK signaling pathway (Kegg) 4.17E-05
Wound healing (BP) 4.64E-05
CRC (Kegg) 6.92E-04
Positive regulation of inflammatory
response (BP)
1.62E-03
ECM organization (BP) 6.74E-03
Fibroblast growth factor receptor
signaling pathway (BP)
4.16E-02
Positive regulation of collagen
biosynthetic process (BP)
1.77E-02
Collagen catabolic process (BP) 2.38E-02
I-kappaB kinase/NF-kappaB cascade (BP) 3.89E-02
Down-regulated genes
DNA repair (BP) 6.52E-11
Mismatch repair (Kegg) 3.39E-04
Nucleotide excision repair (Kegg) 6.92E-04
Base-excision repair (BP) 2.37E-03
*Representative pathways enriched by genes significantly increased or de-
creased 1.5-fold in response to IL-33. Full lists of annotated pathways and
their composing genes can be found in Datasets S2 and S3. BP, Go Biological
Processes; Kegg, Kegg Pathways.
Fig. 5. Abrogation of responsiveness to IL-33 signaling attenuates Th2-associated cytokine expression in polyps. qPCR analysis of (A) Il4, (B) Il13, and (C) Il6
expression in normal mucosa of WT mice and in polyps of ApcMin/+ mice WT (+/+) or deficient (−/−) for Il33 or treated with an IgG control (Cnt) or Il1rl1
antagonist antibody (Ant). Expression is plotted relative to WT ± SEM (n = 5–10). †P ≤ 0.01; ‡P ≤ 0.001; #P ≤ 0.0001.
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epithelial cells coopt mucosal immune and tissue repair responses
to promote tumorigenesis (4, 5). However, other cell types in
normal mucosa surrounding intestinal tumors (e.g., SEMFs) and,
in rare instances, within adenomas (e.g., endothelial cells) ex-
pressed IL-33. Thus, we cannot exclude the possibility that these
cells are an additional/alternative source of cytokine IL-33 in ad-
enomas. A conditional knockout allele of IL-33 will be necessary
to evaluate the relative contribution of IL-33 expression by various
cell types to tumor initiation and progression in the ApcMin/+
mouse model.
The extrinsic or intrinsic factors that induce IL-33 expression
in adenomatous cells remain to be identified. Several studies
previously showed that cytokines and eicosanoids associated with
polyposis, such as TNF, IL-1β, TGFβ, PGE2, and pathogen-as-
sociated molecular patterns, such as lipopolysaccharide (LPS),
induce IL-33 expression and in some instances release a variety of
cell types (25, 26, 28, 38, 64). However, the capacity of in-
flammatory molecules to induce CRC cell line expression and
release of IL-33 has not been consistent among studies (25–27).
Alternatively, intrinsic properties of tumor epithelial cells, alone
or in combination with inflammatory signals, may induce IL-33
expression. In ApcMin/+ polyps, IL-33 expression was localized to
adenomatous cells with abundant nuclear localization of β-catenin.
Thus, loss of heterozygosity for Apc and the constitutive acti-
vation of Wnt signaling may significantly contribute to IEC
expression of Il33 expression. In support of this observation,
IL-33 expression is significantly reduced following RNAi-
mediated knockdown of β-catenin in CRC cell lines DLD1
and LS174T (70).
Interestingly, we found that immunolabeling for IL-33 in the
epithelium of human intestinal tumors decreased as tumors
progressed to the carcinoma stage. Conversely, we observed little
to no immunolabeling for IL1RL1 in adenomatous cells in human
or mouse. However, some carcinoma cells were IL1RL1-positive.
These results suggest that additional genetic alterations or changes
in the microenvironment associated with carcinoma cause the
epithelium to become responsive to IL-33. In fact, studies of head
and neck squamous cell carcinoma (HNSCC), pancreatic carci-
noma, and colon carcinoma cell lines suggest that IL-33 is an
autocrine/paracrine mediator of carcinoma cell invasiveness and
metastasis (30, 67, 68). Thus, at later stages of CRC progression,
IL-33 may directly influence the tumorigenic properties of both
the epithelium and stroma.
Polyposis also significantly altered SEMF expression of IL-33
and IL1RL1. SEMFs are the primary mesenchymal cell type in
the stroma of adenomas, and their activation leads to the pro-
duction and release of several cytokines, growth factors, ECM
components, and angiogenesis factors to form a microenviron-
ment favorable to tumor initiation, progression, and metastasis
(5, 9). In our study, SEMFs surrounding crypts in normal mucosa
and deep crypts under polyp lesions expressed IL-33. However,
within polyp lesions, SEMFs expressed neither IL-33 nor the
LacZ reporter of the IL-33 knockout allele. Instead, polyp-
associated SEMFs expressed IL1RL1, which was surprising
because previous studies of normal and chronically inflamed
intestinal mucosa did not report IL1RL1 expression by SEMFs
(24, 26). Previous studies of human chronic pancreatitis tissues
showed subpopulations of myofibroblasts expressing either IL-33
or IL1RL1. In vitro, pancreatic myofibroblasts expressed IL-33
or IL1RL1 in response to different cytokines: IL-1β, TNF, and
LPS induced IL-33 expression and IL-4 and IFN-γ induced
IL1RL1 expression (38). Thus, based on these observations, it
is feasible that a cytokine milieu specific to polyposis activates
SEMF expression of IL1RL1.
Transcriptional profiling of the human SEMF cell line CCD-
18Co demonstrated that IL-33 activates SEMF expression of
factors that contribute to tumorigenesis (Dataset S1). In particu-
lar, IL-33 induced the expression of several growth factors, in-
cluding fibroblast growth factors (FGF2 and FGF7), nerve growth
factor (NGF), and amphiregulin (AREG), known to promote
epithelial cell proliferation and tumor initiation and progression
(9). Additionally, IL-33 stimulated SEMF expression of matrix
metalloproteinases previously associated with CRC, including
MMP1 and MMP3, which degrade collagens, activate growth
factors, promote tumor invasion, and mediate angiogenesis (43).
IL-33 induced the expression of several additional proangiogenic
factors including VEGFC and IL8 (71, 72). Thus, the decreased
proliferation, increased apoptosis, and reduced vascularization
observed in Il33-deficient ApcMin/+ polyps may be attributed, in
part, to a reduction in SEMF activation. Curiously, IL-33 also
stimulates SEMF expression of TGFB1. TGFB1 is a known
paracrine/autocrine mediator of SEMF differentiation and con-
tributor to stromal cell expression of secreted and membrane-
bound factors that promote carcinoma cell metastasis (11).
SEMF expression of these same TGFβ-induced genes increased
in response to IL-33, suggesting that IL-33 promotes metastasis
through a TGFβ transcriptional program in the tumor stroma.
Interestingly, Liu and coworkers (29) demonstrated that IL-33
acts on CRC cell lines to enhance carcinoma cell metastatic
capacity. Thus, based on this previous study and our expression re-
sults, we propose that IL-33 signaling may alter the transcriptional
Fig. 6. IL-33 signaling deficiency suppresses mast cell number and gene
expression in polyps. (A and B) qPCR expression analysis of mast cell genes
Cma1 and Mcpt4 in normal mucosa of WT mice and in polyps of 90-d-old
ApcMin/+ mice WT (+/+) or deficient (−/−) for Il33, or treated with an IgG
control (Cnt) or Il1rl1 antagonist (Ant) antibody. Expression is plotted rela-
tive to WT ± SEM (n = 5–10). (C and D) Colocalization of IL1RL1 (green) with
the connective tissue mast cell markers tryptase and mucosal mast cell marker
MCPT1 (red) in ApcMin/+ polyps. Nuclei were counterstained with DAPI. (Scale
bars, 25 μm.) (E) Representative images of CAE- and hematoxylin-stained
ApcMin/+ polyps WT or deficient for IL-33. Mast cells are identified as cells with
intensely red-stained granules. (Scale bars, 50 μm.) (F) Mast cells per field were
counted in high-magnification (400×) images of normal WT mucosa (n = 9)
and IL-33 WT (+/+) (n = 24) and deficient (−/−) (n = 18) polyp sections stained for
CAE. Bars indicate the mean.



























profile of both carcinoma cells and tumor stromal cells to pro-
mote CRC metastasis.
In addition to influencing SEMF function, cytokine IL-33 pro-
moted mastocytosis and mast cell activation in ApcMin/+ polyps. In
the intestine, mast cells accumulate at sites of parasite infection to
induce and participate in Th2-mediated immunity and wound
healing (73, 74). Mast cells release a variety of cytokines, proteases,
histamine, eicosanoids, and growth factors that influence diverse
physiological and pathological processes including epithelial cell
proliferation and barrier integrity, granulocyte recruitment, angio-
genesis, wound healing, and fibrosis (75). It is through these factors
that mast cells establish a microenvironment favorable to polyposis
(76). Using Apcmutant and colitis-induced mouse models of CRC,
mast cell recruitment and activation have been shown to promote
IEC survival and proliferation and tumor-associated angiogenesis
(47, 77). It is well recognized that IL-33 induces mast cell pro-
genitor maturation and activates mast cell expression and release
of cytokines (e.g., IL-4, IL-13, and IL-6), chemokines, proteases,
and lipid mediators (46). Thus, our observation that Il33 deficiency
reduced mast cell number and the expression of Il4, Il13, Il6, and
several proteases in polyps is consistent with the established role
for IL-33 in mast cell activation and suggests that IL-33 is an im-
portant mediator of polyp-associated mastocytosis.
In conclusion, we have demonstrated that the IL-33 signaling
network is induced in human CRC and plays an important role in
intestinal polyposis in the ApcMin/+ mouse model. Our observa-
tions imply a model in which the tumor epithelium is a source of
cytokine IL-33 during polyposis and that IL-33 activates at least
two cell types, SEMFs and mast cells, to form a tissue micro-
environment favorable to polyposis. Whether these two cell types
independently influence different aspects (e.g., proliferation
versus angiogenesis) or stages (e.g., initiation versus growth) of
polyposis or cooperatively induce several protumorigenic phenotypes
remains to be resolved. However, because SEMF- and mast cell-
derived factors (e.g., matrix metalloproteinases from SEMFs and
chymases from mast cells) interact to regulate ECM remodeling
and IEC homeostasis (78), cooperative functions during polyposis
are possible. Importantly, results from our assessment of IL-33
expression in CRC patients agree with previous analyses (29, 30)
and suggest that IL-33 plays a similar role in progression of the
human disease. Significantly, the ability of an IL1RL1 antagonist
antibody to reduce tumor initiation and growth in the ApcMin/+
mouse model suggests that IL-33 signaling may be a useful target
for CRC prevention or therapy.
Materials and Methods
Human Tissues and Cell Lines. For serum samples, patients with metastatic
colon cancer treated at the University of Southern California/Norris Com-
prehensive Cancer Center (USC/NCCC) or the Los Angeles County + USC
Medical Center (LAC+USCMC) between 1992 and 2003 were eligible for this
study. This population included only metastatic or recurrent colon cancer
patients. All patients in this study signed informed consents and enrolled in
protocols designed to study the molecular determinants of colon cancer.
These protocols permitted blood collection and/or tissue collection. All en-
rolled patients were followed with an institutional database. Patient in-
formation was collected through database review and retrospective chart
review when additional patient information was necessary. A large number
of the patients (220/318 = 69%) were initially treated at an outside in-
stitution until, because of failure to respond to previous treatment, they
were referred to USC/NCCC or LAC+USCMC for future treatments. All 318
patients were enrolled in at least one chemotherapy clinical trial while being
treated at this institution (USC/NCCC or LAC+USCMC). All patients were
treated with 5-fluorouracil–based chemotherapy regimens. Response to
chemotherapy was not investigated as an end point for this study. This is a
heavily pretreated cohort, with 20 patients (6%) treated with one line of
chemotherapy, 19 patients (6%) treated with two different chemotherapy
regimens, 183 patents (58%) treated with three different chemotherapy
regimens, and 96 patients (30%) treated with four chemotherapy regimens.
Although the treatment regimens varied among patients, the majority of
patients were exposed to similar chemotherapies. All 318 patients (100%)
received treatment with 5-fluorouracil, 298 patients (94%) received treat-
ment with 5-fluorouracil/irinotecan (CPT-11), and 279 patients (88%) re-
ceived treatment with 5-fluorouracil/oxaliplatin. For RNA samples, the
patient population from which colon adenocarcinoma and adjacent normal
tissue biopsies were collected and cell lines were derived was previously
described (79). Representative examples of colonic adenocarcinomas and
corresponding normal colonic mucosa were obtained as discarded tissue
samples from the Tissue Procurement Service of the Case Comprehensive
Cancer Center under an Internal Review Board-approved protocol at Uni-
versity Hospitals Case Medical Center.
Quantification of IL-33 Serum Protein Levels. Whole blood was drawn from
patients with stage 4 metastatic, colorectal adenocarcinomas and healthy
individuals using a 22-gauge syringe into red-topped vaccutainers and
centrifuged for 10 min at 500 × g. Serum was collected from each sample,
immediately aliquoted, and stored at –80 °C until further assayed. All studies
were approved by the Internal Review Board of the Keck School of Medicine
of USC. Human serum IL-33 concentrations were measured using the IL-33
(human) ELISA kit (Enzo Life Sciences).
Microarray Reanalysis of IL33 Expression in Human CRC. Primary sources for the
tumor expression data obtained from theOncomine Database (www.oncomine.
org) were as follows: Skrzypczak colorectal 1 and 2 (31) and Sabates-Bellver
Colon (32). Data are available in the Gene Expression Omnibus (GEO) database
[accession nos. GSE2091 (Skrzypczak colorectal 1 and 2) and GSE871 (Sabates-
Bellver Colon) at www.ncbi.nlm.nih.gov/geo].
Animals. C57BL/6J (B6, JR000664), C57BL/6J-ApcMin/+/J (B6.ApcMin/+, JR002020),
and B6.C-Tg(CMV-cre)1Cgn/J (B6.CMV-Cre, JR006054) mice were purchased
from The Jackson Laboratory. C57BL/6NCrl mice harboring an engineered
Il33 knockout–LacZ knock-in allele (Il33tm1(KOMP)Vlcg) (Fig. S2A) were
obtained from Regeneron through the Knockout Mouse Project (KOMP)
and backcrossed for 10 generations to C57BL/6J. Before use in studies,
breeding heterozygous B6-Il33tm1(KOMP)Vlcg/+ mice to B6.CMV-Cre mice
removed the loxP flanked neomycin selectable marker in the knockout
allele. PCR genotyping with primers Flox-1 5′-GCAATAGCATCACAAATTTC-
ACA-3′, Flox-2 5′-CCCAAGTCCCGTCCTAAAAT-3′, and Flox-3 5′-TCGGTTGTT-
TTCTTGTTTTGC-3′ verified excision of the neomycin selection cassette (Fig.
S2B). A PCR assay using primers WT-F 5′-TCCTGCCTCCCTGAGTACAT-3′, WT-R
5′-TTGCTCTTGGTCTTTTCCAGA-3′, KO-F 5′-AACAGTACTGAGATTTCAACAC-3′,
and KO-R 5′-GTCTGTCCTAGCTTCCTCACTG-3′ was used to identify WT,
heterozygous, and homozygous Il33 knockout mice (Fig. S2C).
Animals were housed in the Transgenic Mouse Facility at Baylor College of
Medicine (BCM) with the exception of those used for antibody injection
studies, which were housed at the Wolstein Research Facility at Case Western
Reserve University (CWRU). Animals were maintained on a 12-h light/dark
cycle and fed the Purina 5010 LabDiet (CWRU) or the Harlan 2920x diet (BCM).
For IL1RL1 antagonism studies, B6-ApcMin/+ were injected intraperitoneally
with 150 μg of monoclonal anti-IL1RL1 (mu-IgG1-FC–anti-muST2, Amgen) or
control IgG (4D2-mu-IgG1–anti-huAGP3-Pb, Amgen) twice a week from 21 to
90 d of age. For all studies, 90-d-old mice were euthanized by carbon dioxide,
and the small and large intestines were removed, flushed with cold PBS, and
cut longitudinally. Polyps were counted and their diameter was measured in
the small intestine and colon using a Leica MZ10F Modular Stereomicroscope.
All procedures were approved and conducted in compliance with Institutional
Animal Care and Use Committee standards at BCM and CWRU.
qRT-PCR. RNA from frozen colon adenocarcinoma tissues and adjacent control
tissues was extracted using a GIT/cesium gradient. Size-matched (1 mm)
polyps from B6.ApcMin/+ mice and normal mucosa from B6.Apc+/+ age-
matched littermates were scraped from the ileum or jejunum of the small
intestine, and RNA was extracted using the Qiagen RNeasy Mini Kit. RNA
was reverse transcribed with the SuperScript First-Strand Synthesis System
(Life Technologies), and qRT-PCR was performed using the Roche FastStart
Universal SYBR Green Master Mix (04913850001). Relative expression was
calculated using Rpl7 and 18s as a housekeeping gene for mouse and human
tissues, respectively, and the ΔΔCt analysis method. Primer sequences are
available upon request.
Immunohistochemistry. Intestinal tissues (ileum and jejunum) from 90-d-old
mice and human CRC biopsies (colon) were fixed in 4% (wt/vol) para-
formaldehyde, embedded into paraffin blocks, and cut into 5-μm sections.
Tissue sections were deparaffinized, processed for antigen retrieval in so-
dium citrate buffer (pH 6.0), and blocked in 5% (vol/vol) donkey serum, 3%
(wt/vol) BSA, and 0.3% Triton X-100 in 1× PBS. Sections were incubated with
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primary antibodies (Table S1) overnight at 4 °C. For angiogenesis assays,
antigen retrieval was performed in Target Retrieval Solution (S170084, Dako),
and sections were incubated with primary antibody for 1.5 h at room tem-
perature. For detection by fluorescence microscopy, sections were incubated
with 1:400 dilutions of donkey anti-goat AlexaFluor 488 (A-11055, Life Tech-
nologies), donkey anti-mouse 594 (A-21203, Life Technologies), donkey
anti-rabbit 594 (A21207, Life Technologies), donkey anti-rat 594 (A21209,
Life Technologies), or donkey anti-chicken 594 (703-585-155, Jackson
ImmunoResearch) secondary antibodies. For confocal microscopy, sections were
incubated with 1:400 dilutions of donkey anti-goat AlexaFluor 488, donkey
anti-mouse 555 (A31570, Life Technologies), or donkey anti-chicken 647 (703-
606-155, Jackson ImmunoResearch) secondary antibodies. Nuclei were coun-
terstained with DAPI. For secondary detection by immunohistochemistry, sec-
tions were incubated with 1:300 dilutions of biotin-labeled anti-rabbit (ab6801)
or anti-goat (ab6884) antibodies and stained using streptavidin–horseradish
peroxidase (HRP) (20774, Millipore) and 3,3′-diaminobenzidine (DAB) substrate
(SK-4100, Vector Labs) according to the manufacturers’ instructions.
Proliferation and Apoptosis Assays. For BrdU incorporation assays, mice were
injected at 90 d of age with 400 μL of 10 mg/mL BrdU (BD Pharmingen). Four
hours after injection, animals were euthanized and the small and large in-
testines were immediately removed, flushed with cold PBS, fixed overnight
at 4 °C in 4% paraformaldehyde, and processed for paraffin embedding.
Deparaffinized sections of polyps (5 μm) were immunolabeled for BrdU in-
corporation using the Millipore BrdU Cell Proliferation Kit (2750) according
to the manufacturer’s instructions and counterstained with hematoxylin. For
TUNEL assays, deparaffinized sections of polyps (5 μm) were labeled with the
ApopTag Direct In Situ Apoptosis Detection Kit (Millipore, S7160) according
to the manufacturer’s instructions. Digoxigenin-labeled NTPs and a fluores-
cein-conjugated antidigoxigenin antibody were used to visualize products of
the terminal deoxynucleotidyl transferase (Tdt) reactions. Nuclei were coun-
terstained with DAPI.
Human SEMF Cell Line Culture and Whole Transcriptome Sequencing (RNA-seq).
Cell line CCD18Co (ATCC, CRL-1459) was cultured in T-75 flasks in Eagle’s
minimum essential medium (EMEM) (112-018-101, Quality Biologicals) sup-
plemented with 10% (vol/vol) FBS (10437, Life Technologies), 1× non-
essential amino acids (11140, Life Technologies), and 100 U/mL penicillin–
streptomycin (15140, Life Technologies) at 37 °C and 5% CO2. At 80% con-
fluency, new medium supplemented with 10 ng/mL recombinant human
IL-33 (3625-IL/CF, R&D Systems) or vehicle control (1× PBS) was added, and
cells were cultured for an additional 6 h. RNA was processed in triplicate for
each condition using the Qiagen RNeasy Mini Kit. Sequencing libraries were
prepared and 6-plex barcoded with the Illumina TruSeq RNA Sample Prep Kit
V2 and subjected to 100 cycles of paired-end sequencing on two flow cell
lanes using an Illumina HiSEq. 2000 platform. Sequencing resulted in an
average of 65 million paired-end reads per sample. RNA-seq data were
assessed for quality using FastQC. Adapter sequences were removed and
low-quality bases were trimmed from reads, reads were quality filtered, and
sample reads were concatenated. The TopHat and Cufflinks V2.1.1 software
packages were used to align and assemble reads using the UCSC hg19 ge-
nome and transcript annotation files (support.illumina.com/sequencing/
sequencing_software/igenome.html) as references. Differential expression
between control and IL-33–treated conditions was assessed using the Cuffdiff
module of Cufflinks with a false discovery rate of 0.05. IL-33–regulated
mRNAs were defined as those with more than a 1.5-fold higher or lower
expression (P < 0.05). All software was accessed through the Galaxy Server
(galaxyproject.org). Functional annotation of up- and down-regulated mRNAs
(1.5-fold, P < 0.05) was performed using the KEGG Pathways and GO Biological
Processes annotations accessed through GeneCodis (genecodis.cnb.csic.es)
(80). Data are available in the GEO database (accession no. GSE62518).
CAE Staining. Intestinal tissues were fixed in 4% paraformaldehyde, em-
bedded in paraffin blocks, and cut into 5-μm sections. Deparaffinized sections
were stained for CAE with the Naphthol-AS-D chloroacetate (specific ester-
ase) kit (91C-1KT, Sigma) and counterstained with hematoxylin according to
the manufacturer’s instructions.
Image Acquisition and Analysis. Bright field and fluorescence microscopy
images of tissue sections were collected with a Zeiss Axioplan2 microscope.
Confocal images of sections were taken with a Nikon A1-Rs inverted Laser
Scanning Microscope. For BrdU and TUNEL assays, nuclei were counted in
images (magnification, 400×) with the ImageJ Software program and the
plugin “ITCN” to determine total cell number. BrdU- and TUNEL-positive
cells in sections were enumerated with the ImageJ plugin “Cell Counter,”
and the percentage of positive cells per section was calculated in four polyp
sections from four mice for each genotype (a total of 16 polyp sections
analyzed per genotype). Vessel area density was calculated using methods
previously described (47). Briefly, the ImageJ Software command “color
threshold” was used to identify regions of vWF-positive cell staining and
tissue background staining in 400× images of polyp sections. The total area
occupied by vWF-positive vessels (≥60 μm2), including hollow structures, and
background tissue staining was determined using the command “analyze
particles.” Vessel area density was calculated as the percentage of the vWF-
positive area divided by the total tumor area in four polyp sections from
four mice for each genotype (a total of 16 polyp sections analyzed per ge-
notype). CAE-positive cells in mucosal and polyp sections were counted
(magnification, 400×) with the ImageJ plugin Cell Counter.
Statistical Analysis. Analyses were performed with the Prism6 software. One-
way ANOVA, 95% confidence intervals, with Bonferroni’s multiple com-
parisons posttests was used for analyses of mouse and human gene ex-
pression data. ELISA results were analyzed by unpaired t test with Welch’s
correction. Polyp number, polyp size, CAE staining, BrdU incorporation, and
TUNEL assay results were analyzed by unpaired t tests.
ACKNOWLEDGMENTS. We thank Dr. Graham Casey (USC) for his assistance
with identifying CRC patient serum samples and his helpful discussions. We
also thank Kay Washington (Vanderbilt University) for assistance with tumor
pathology. Finally, we thank Dirk Smith, PhD, and Amgen for providing the
IL1RL1 antagonist and control antibodies. We thank the Baylor College of
Medicine Genetically Engineered Mouse, Human Tissue Acquisition and
Pathology, Genomic and RNA Profiling, and Integrated Microscopy Ad-
vanced Technologies Cores for assistance with mouse rederivation, tissue
processing, next generation whole transcriptome sequencing, and confocal
microscopy, respectively. Resources accessed through all cores were sup-
ported by National Institutes of Health (NIH)–National Cancer Institute Grant
CA125123 to the Dan L. Duncan Cancer Center. Additionally, NIH Grants
HD007495 and DK56338 and a grant from the John S. Dunn Gulf Coast
Consortium for Chemical Genomics supported resources accessed through
the Integrated Microscopy Core. This work was supported by the Caroline
Wiess Law Fund for Research in Molecular Medicine (to J.D.H.), the De Gre-
gorio Family Foundation (to T.T.P.), and NIH Grants CA150964 (to S.D.M.),
RR12305 (to J.H.N.), and DK056762 (to T.T.P.).
1. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87(2):
159–170.
2. Powell SM, et al. (1992) APC mutations occur early during colorectal tumorigenesis.
Nature 359(6392):235–237.
3. Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in
colorectal cancer. Nat Rev Cancer 1(1):55–67.
4. Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer.
Gastroenterology 138(6):2101–2114, e5.
5. Powell DW, Adegboyega PA, Di Mari JF, Mifflin RC (2005) Epithelial cells and their
neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am
J Physiol Gastrointest Liver Physiol 289(1):G2–G7.
6. Gause WC, Wynn TA, Allen JE (2013) Type 2 immunity and wound healing: Evolu-
tionary refinement of adaptive immunity by helminths. Nat Rev Immunol 13(8):
607–614.
7. Owens BM, Simmons A (2013) Intestinal stromal cells in mucosal immunity and ho-
meostasis. Mucosal Immunol 6(2):224–234.
8. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell
144(5):646–674.
9. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation
and progression. Nature 432(7015):332–337.
10. Elenbaas B, Weinberg RA (2001) Heterotypic signaling between epithelial tumor cells
and fibroblasts in carcinoma formation. Exp Cell Res 264(1):169–184.
11. Calon A, et al. (2012) Dependency of colorectal cancer on a TGF-β-driven program in
stromal cells for metastasis initiation. Cancer Cell 22(5):571–584.
12. Tsushima H, et al. (2001) Circulating transforming growth factor beta 1 as a predictor
of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7(5):1258–1262.
13. Lopetuso LR, Scaldaferri F, Pizarro TT (2012) Emerging role of the interleukin (IL)-33/
ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair 5(1):18.
14. Wood IS, Wang B, Trayhurn P (2009) IL-33, a recently identified interleukin-1 gene family
member, is expressed in human adipocytes. Biochem Biophys Res Commun 384(1):105–109.
15. Moussion C, Ortega N, Girard JP (2008) The IL-1-like cytokine IL-33 is constitutively
expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel
‘alarmin’? PLoS ONE 3(10):e3331.
16. Schmitz J, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1
receptor-related protein ST2 and induces T helper type 2-associated cytokines. Im-
munity 23(5):479–490.



























17. Carriere V, et al. (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a
chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104(1):282–287.
18. Saenz SA, Taylor BC, Artis D (2008) Welcome to the neighborhood: Epithelial cell-
derived cytokines license innate and adaptive immune responses at mucosal sites.
Immunol Rev 226:172–190.
19. Lüthi AU, et al. (2009) Suppression of interleukin-33 bioactivity through proteolysis by
apoptotic caspases. Immunity 31(1):84–98.
20. Chackerian AA, et al. (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33
receptor complex. J Immunol 179(4):2551–2555.
21. Hayakawa H, Hayakawa M, Kume A, Tominaga S (2007) Soluble ST2 blocks interleukin-33
signaling in allergic airway inflammation. J Biol Chem 282(36):26369–26380.
22. Lopetuso LR, Chowdhry S, Pizarro TT (2013) Opposing functions of classic and novel
IL-1 family members in gut health and disease. Front Immunol 4:181.
23. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK (2008) IL-33, a potent in-
ducer of adaptive immunity to intestinal nematodes. J Immunol 180(4):2443–2449.
24. Beltrán CJ, et al. (2010) Characterization of the novel ST2/IL-33 system in patients with
inflammatory bowel disease. Inflamm Bowel Dis 16(7):1097–1107.
25. Kobori A, et al. (2010) Interleukin-33 expression is specifically enhanced in inflamed
mucosa of ulcerative colitis. J Gastroenterol 45(10):999–1007.
26. Pastorelli L, et al. (2010) Epithelial-derived IL-33 and its receptor ST2 are dysregulated
in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci
USA 107(17):8017–8022.
27. Seidelin JB, et al. (2010) IL-33 is upregulated in colonocytes of ulcerative colitis. Im-
munol Lett 128(1):80–85.
28. Sponheim J, et al. (2010) Inflammatory bowel disease-associated interleukin-33 is
preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol 177(6):
2804–2815.
29. Cui G, et al. (2015) Dynamics of the IL-33/ST2 network in the progression of human
colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother 64(2):
181–190.
30. Liu X, et al. (2014) IL-33/ST2 pathway contributes to metastasis of human colorectal
cancer. Biochem Biophys Res Commun 453(3):486–492.
31. Skrzypczak M, et al. (2010) Modeling oncogenic signaling in colon tumors by multi-
directional analyses of microarray data directed for maximization of analytical re-
liability. PLoS ONE 5(10).
32. Sabates-Bellver J, et al. (2007) Transcriptome profile of human colorectal adenomas.
Mol Cancer Res 5(12):1263–1275.
33. Taketo MM, Edelmann W (2009) Mouse models of colon cancer. Gastroenterology
136(3):780–798.
34. Palmer G, et al. (2009) Inhibition of interleukin-33 signaling attenuates the severity of
experimental arthritis. Arthritis Rheum 60(3):738–749.
35. Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold
Spring Harb Perspect Biol 1(5):a000141.
36. Choi YS, et al. (2009) Interleukin-33 induces angiogenesis and vascular permeability
through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 114(14):
3117–3126.
37. Powell DW, et al. (1999) Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am
J Physiol 277(2 Pt 1):C183–C201.
38. Nishida A, et al. (2010) Expression of interleukin 1-like cytokine interleukin 33 and its
receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 59(4):
531–541.
39. Andoh A, Bamba S, Brittan M, Fujiyama Y, Wright NA (2007) Role of intestinal sub-
epithelial myofibroblasts in inflammation and regenerative response in the gut.
Pharmacol Ther 114(1):94–106.
40. Andoh A, Bamba S, Fujiyama Y, Brittan M, Wright NA (2005) Colonic subepithelial
myofibroblasts in mucosal inflammation and repair: Contribution of bone marrow-
derived stem cells to the gut regenerative response. J Gastroenterol 40(12):1089–1099.
41. Andoh A, Fujino S, Okuno T, Fujiyama Y, Bamba T (2002) Intestinal subepithelial
myofibroblasts in inflammatory bowel diseases. J Gastroenterol 37(Suppl 14):33–37.
42. Hinterleitner TA, Saada JI, Berschneider HM, Powell DW, Valentich JD (1996) IL-1
stimulates intestinal myofibroblast COX gene expression and augments activation of
Cl- secretion in T84 cells. Am J Physiol 271(4 Pt 1):C1262–C1268.
43. Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal
cancer. Cancer Metastasis Rev 23(1-2):101–117.
44. Mukaratirwa S, de Witte E, van Ederen AM, Nederbragt H (2003) Tenascin expression
in relation to stromal tumour cells in canine gastrointestinal epithelial tumours.
J Comp Pathol 129(2-3):137–146.
45. Lunderius-Andersson C, Enoksson M, Nilsson G (2012) Mast cells respond to cell injury
through the recognition of IL-33. Front Immunol 3:82.
46. Enoksson M, et al. (2011) Mast cells as sensors of cell injury through IL-33 recognition.
J Immunol 186(4):2523–2528.
47. Gounaris E, et al. (2007) Mast cells are an essential hematopoietic component for
polyp development. Proc Natl Acad Sci USA 104(50):19977–19982.
48. Blatner NR, et al. (2010) In colorectal cancer mast cells contribute to systemic regu-
latory T-cell dysfunction. Proc Natl Acad Sci USA 107(14):6430–6435.
49. Cheon EC, et al. (2011) Mast cell 5-lipoxygenase activity promotes intestinal polyposis
in APCDelta468 mice. Cancer Res 71(5):1627–1636.
50. Gurish MF, Boyce JA (2006) Mast cells: Ontogeny, homing, and recruitment of a
unique innate effector cell. J Allergy Clin Immunol 117(6):1285–1291.
51. Friend DS, et al. (1996) Mast cells that reside at different locations in the jejunum of
mice infected with Trichinella spiralis exhibit sequential changes in their granule ul-
trastructure and chymase phenotype. J Cell Biol 135(1):279–290.
52. Dalgleish AG, O’Byrne KJ (2002) Chronic immune activation and inflammation in the
pathogenesis of AIDS and cancer. Adv Cancer Res 84:231–276.
53. Kidd P (2003) Th1/Th2 balance: The hypothesis, its limitations, and implications for
health and disease. Altern Med Rev 8(3):223–246.
54. Terabe M, Park JM, Berzofsky JA (2004) Role of IL-13 in regulation of anti-tumor
immunity and tumor growth. Cancer Immunol Immunother 53(2):79–85.
55. Romagnani S (1997) The Th1/Th2 paradigm. Immunol Today 18(6):263–266.
56. Arwert EN, Hoste E, Watt FM (2012) Epithelial stem cells, wound healing and cancer.
Nat Rev Cancer 12(3):170–180.
57. O’Hara RJ, et al. (1998) Advanced colorectal cancer is associated with impaired in-
terleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 4(8):1943–1948.
58. Pellegrini P, et al. (1996) Disregulation in TH1 and TH2 subsets of CD4+ T cells in
peripheral blood of colorectal cancer patients and involvement in cancer establish-
ment and progression. Cancer Immunol Immunother 42(1):1–8.
59. Shibata M, et al. (2002) Decreased production of interleukin-12 and type 2 immune
responses are marked in cachectic patients with colorectal and gastric cancer. J Clin
Gastroenterol 34(4):416–420.
60. Kurzrock R (2001) Cytokine deregulation in cancer. Biomed Pharmacother 55(9-10):
543–547.
61. Nakanishi Y, et al. (2011) COX-2 inhibition alters the phenotype of tumor-associated
macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 32(9):
1333–1339.
62. Kojima M, et al. (2001) Association of enhanced cyclooxygenase-2 expression with
possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol
8(5):458–465.
63. Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol
188(1):21–28.
64. Yanagawa Y, Suzuki M, Matsumoto M, Togashi H (2011) Prostaglandin E(2) enhances
IL-33 production by dendritic cells. Immunol Lett 141(1):55–60.
65. Jovanovic I, et al. (2011) ST2 deletion enhances innate and acquired immunity to
murine mammary carcinoma. Eur J Immunol 41(7):1902–1912.
66. Jovanovic IP, et al. (2014) Interleukin-33/ST2 axis promotes breast cancer growth and
metastases by facilitating intratumoral accumulation of immunosuppressive and in-
nate lymphoid cells. Int J Cancer 134(7):1669–1682.
67. Chen SF, et al. (2013) The paracrine effect of cancer-associated fibroblast-induced
interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma.
J Pathol 231(2):180–189.
68. Schmieder A, Multhoff G, Radons J (2012) Interleukin-33 acts as a pro-inflammatory
cytokine and modulates its receptor gene expression in highly metastatic human
pancreatic carcinoma cells. Cytokine 60(2):514–521.
69. Li J, et al. (2014) Biliary repair and carcinogenesis are mediated by IL-33-dependent
cholangiocyte proliferation. J Clin Invest 124(7):3241–3251.
70. Herbst A, et al. (2014) Comprehensive analysis of β-catenin target genes in colorectal
carcinoma cell lines with deregulated Wnt/β-catenin signaling. BMC Genomics 15:74.
71. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69
(Suppl 3):4–10.
72. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res
14(21):6735–6741.
73. Voehringer D (2013) Protective and pathological roles of mast cells and basophils. Nat
Rev Immunol 13(5):362–375.
74. Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat
Rev Immunol 10(6):440–452.
75. Bischoff SC (2009) Physiological and pathophysiological functions of intestinal mast
cells. Semin Immunopathol 31(2):185–205.
76. Maltby S, Khazaie K, McNagny KM (2009) Mast cells in tumor growth: Angiogenesis,
tissue remodelling and immune-modulation. Biochim Biophys Acta 1796(1):19–26.
77. Wedemeyer J, Galli SJ (2005) Decreased susceptibility of mast cell-deficient Kit(W)/Kit
(W-v) mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors.
Lab Invest 85(3):388–396.
78. Groschwitz KR, Wu D, Osterfeld H, Ahrens R, Hogan SP (2013) Chymase-mediated
intestinal epithelial permeability is regulated by a protease-activating receptor/matrix
metalloproteinase-2-dependent mechanism. Am J Physiol Gastrointest Liver Physiol
304(5):G479–G489.
79. Sjöblom T, et al. (2006) The consensus coding sequences of human breast and co-
lorectal cancers. Science 314(5797):268–274.
80. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A (2007)
GENECODIS: A web-based tool for finding significant concurrent annotations in gene
lists. Genome Biol 8(1):R3.
E2496 | www.pnas.org/cgi/doi/10.1073/pnas.1422445112 Maywald et al.
